Reviewed Mar 2026 | PubMed sources
Active Market
United Kingdom is selected. The evidence comparison is still valid, but provider availability, legal positioning, and cost assumptions may still be staged for later rollout.

Tirzepatide vs Tesamorelin: Head-to-Head Comparison

Both are FDA-approved peptides affecting metabolic pathways. Tirzepatide (dual GIP/GLP-1 agonist) produces dramatic overall weight loss, while tesamorelin (GHRH analog) specifically reduces visceral fat via GH pathway. Tirzepatide achieves greater total weight loss, but tesamorelin targets visceral adiposity specifically.

Approved Comparison Routing

Approved options in this comparison

A
Tirzepatide

Tirzepatide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Mounjaro, Zepbound.

A
Tesamorelin

Tesamorelin is currently modeled on this site as an approved treatment path for: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Brand names in the current dataset: Egrifta, Egrifta SV.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Need help choosing between prescribing paths?

One or more options in this comparison are currently modeled on this site as approved treatment paths. Use the provider matcher to narrow the best next step based on your budget, insurance, and timeline.

Join provider rollout

Side-by-Side Comparison

DimensionTirzepatideTesamorelin
Evidence LevelPhase III trials (SURMOUNT/SURPASS)Phase III trials for HIV lipodystrophy
FDA StatusFDA-approved for T2D and obesityFDA-approved for HIV lipodystrophy
MechanismDual GIP/GLP-1 receptor agonismGHRH receptor agonism, GH/IGF-1 elevation
Weight Loss Efficacy~20-22.5% total body weight lossTargeted visceral fat reduction (~15-18%)
Muscle ImpactSignificant lean mass loss (~25-40% of weight lost)GH pathway may preserve lean mass
Side EffectsGI effects (nausea, vomiting, diarrhea)Arthralgia, edema, injection site reactions
CostVery high (~$1,000+/month)Very high (~$800-1,000+/month)
Evidence Level
Tirzepatide
Phase III trials (SURMOUNT/SURPASS)
Tesamorelin
Phase III trials for HIV lipodystrophy
FDA Status
Tirzepatide
FDA-approved for T2D and obesity
Tesamorelin
FDA-approved for HIV lipodystrophy
Mechanism
Tirzepatide
Dual GIP/GLP-1 receptor agonism
Tesamorelin
GHRH receptor agonism, GH/IGF-1 elevation
Weight Loss Efficacy
Tirzepatide
~20-22.5% total body weight loss
Tesamorelin
Targeted visceral fat reduction (~15-18%)
Muscle Impact
Tirzepatide
Significant lean mass loss (~25-40% of weight lost)
Tesamorelin
GH pathway may preserve lean mass
Side Effects
Tirzepatide
GI effects (nausea, vomiting, diarrhea)
Tesamorelin
Arthralgia, edema, injection site reactions
Cost
Tirzepatide
Very high (~$1,000+/month)
Tesamorelin
Very high (~$800-1,000+/month)

Peptide Overviews

Tirzepatide

AFDA Approved

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.

Weight LossFDA Approved
View full Tirzepatide profile →

Tesamorelin

AFDA Approved

Tesamorelin is a synthetic GHRH analog approved by the FDA as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Growth Hormone SecretagoguesFDA Approved
View full Tesamorelin profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Tirzepatide vs Tesamorelin: FAQ